Kainova Therapeutics

Clinical-stage biopharmaceutical developer advancing GPCR‑modulating therapies to improve outcomes in immuno-oncology and inflammatory diseases, including a Treg‑depleting anti‑CCR8 antibody and a first‑in‑class biased PAR2 antagonist.
Load...
Load...
Load...
Load...
Load...
Employees
loading...
Funding Status
loading...
Established
loading...
Total Funding
loading...
ARR
loading...

Insights

Loading Insights...
Q1/2040}
Loading Insight content to display...
Loading Insights...
Q1/2040}
Loading Insight content to display...
Founders
loading...
Notable Customers
loading...

Funding

Workforce

Functional Distribution
N/A
Open Positions
N/A
Diversity
N/A
Loading